Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
Executive Summary
FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use
You may also be interested in...
Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch
Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch
Stable Cancer Patients Phase I Dosing Could Be Extended If Benefit Shown
A Phase I trial participant should be allowed to continue receiving an investigational oncology compound beyond the duration of animal safety data if he has stable disease and he and his physician agree that this represents a benefit from therapy, FDA's Oncologic Drugs Advisory Committee said March 13